Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT02535364 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.

NCT NCT02535364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02535364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Phase
Phase 2
Overall status
Terminated
Start date
August 21, 2015
Completion date
September 1, 2017
Enrollment
82 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia